花旗发表研究报告，认为复宏汉霖即将在世界肺癌大会(WCLC)公布HLX43的最新数据，将进一步揭示其在非小细胞肺癌(NSCLC)治疗的潜力。若HLX43能在更多样本中维持35%至40%的客观缓解率(ORR)及约5.5个月的无恶化生存期(mPFS)，有关数据将会极具说服力。该行估计，针对三线NSCLC治疗的全球研究最早可于2026年上半年启动。 该行估算HLX43的经风险调整销售高峰可达约23亿美元，如果在NSCLC及其他适应症方面取得更多数据，仍有上行空间。该行亦注意到HLX22及斯鲁利单抗(Serplulimab)的估值尚未被投资者充分反映。该行将评级由“中性”上调至“买入”，目标价由35港元上调至95港元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.